SANA -Sana Biotechnology, Inc.
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=SANA
#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=SANA
&conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]
Float Short %
19.96
Margin Of Safety %
Put/Call OI Ratio
0.13
EPS Next Q Diff
0.05
EPS Last/This Y
0.41
EPS This/Next Y
0.18
Price
4.63
Target Price
8
Analyst Recom
1.25
Performance Q
53.31
Relative Volume
1
Beta
1.95
Ticker: SANA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | SANA | 4.11 | 0.15 | 0.10 | 48038 |
| 2025-11-11 | SANA | 4.25 | 0.15 | 0.10 | 48289 |
| 2025-11-12 | SANA | 4.06 | 0.15 | 0.30 | 48627 |
| 2025-11-13 | SANA | 3.66 | 0.15 | 0.18 | 48657 |
| 2025-11-14 | SANA | 3.97 | 0.15 | 0.06 | 48866 |
| 2025-11-17 | SANA | 3.63 | 0.15 | 0.55 | 49189 |
| 2025-11-18 | SANA | 3.5 | 0.14 | 0.50 | 49304 |
| 2025-11-19 | SANA | 3.4 | 0.14 | 0.02 | 49384 |
| 2025-11-20 | SANA | 3.22 | 0.14 | 0.03 | 49234 |
| 2025-11-21 | SANA | 3.28 | 0.12 | 0.02 | 49149 |
| 2025-11-24 | SANA | 3.55 | 0.12 | 0.01 | 40581 |
| 2025-11-25 | SANA | 3.51 | 0.12 | 0.25 | 41012 |
| 2025-11-26 | SANA | 4.03 | 0.12 | 0.04 | 41208 |
| 2025-12-01 | SANA | 4.01 | 0.14 | 0.37 | 46170 |
| 2025-12-02 | SANA | 3.96 | 0.14 | 0.02 | 46830 |
| 2025-12-03 | SANA | 4.47 | 0.14 | 0.03 | 47186 |
| 2025-12-04 | SANA | 5.2 | 0.14 | 0.06 | 48312 |
| 2025-12-05 | SANA | 5.14 | 0.13 | 0.05 | 49662 |
| 2025-12-08 | SANA | 4.62 | 0.13 | 0.20 | 50222 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | SANA | 4.12 | 29.5 | -25.2 | -0.79 |
| 2025-11-11 | SANA | 4.24 | 29.5 | -21.2 | -0.79 |
| 2025-11-12 | SANA | 4.07 | 29.5 | 92.8 | -0.79 |
| 2025-11-13 | SANA | 3.65 | 29.5 | 99.5 | -0.79 |
| 2025-11-14 | SANA | 3.97 | 56.5 | 77.8 | -0.78 |
| 2025-11-17 | SANA | 3.63 | 56.5 | 98.4 | -0.78 |
| 2025-11-18 | SANA | 3.50 | 56.5 | 92.1 | -0.76 |
| 2025-11-19 | SANA | 3.40 | 56.5 | 92.3 | -0.76 |
| 2025-11-20 | SANA | 3.23 | 56.5 | 94.1 | -0.75 |
| 2025-11-21 | SANA | 3.28 | 42.8 | 86.0 | -0.75 |
| 2025-11-24 | SANA | 3.55 | 42.8 | 78.1 | -0.75 |
| 2025-11-25 | SANA | 3.51 | 42.8 | 89.1 | -0.75 |
| 2025-11-26 | SANA | 4.04 | 42.8 | 70.5 | -0.75 |
| 2025-12-01 | SANA | 4.00 | 42.8 | 95.9 | -0.75 |
| 2025-12-02 | SANA | 3.97 | 42.8 | 88.8 | -0.75 |
| 2025-12-03 | SANA | 4.47 | 42.8 | 73.5 | -0.75 |
| 2025-12-04 | SANA | 5.20 | 42.8 | 69.5 | -0.75 |
| 2025-12-05 | SANA | 5.13 | 42.8 | 89.1 | -0.75 |
| 2025-12-08 | SANA | 4.63 | 42.8 | - | -0.75 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | SANA | 0.00 | -0.50 | 18.99 |
| 2025-11-11 | SANA | 0.00 | -0.50 | 18.99 |
| 2025-11-12 | SANA | 0.00 | -0.50 | 19.29 |
| 2025-11-13 | SANA | 0.00 | -0.50 | 19.29 |
| 2025-11-14 | SANA | 0.00 | -0.50 | 19.29 |
| 2025-11-17 | SANA | 0.00 | 4.41 | 19.29 |
| 2025-11-18 | SANA | 0.00 | 4.41 | 19.29 |
| 2025-11-19 | SANA | 0.00 | 4.41 | 19.29 |
| 2025-11-20 | SANA | 0.00 | 4.41 | 19.29 |
| 2025-11-21 | SANA | 0.00 | 4.41 | 19.29 |
| 2025-11-24 | SANA | 0.00 | 8.38 | 19.29 |
| 2025-11-25 | SANA | 0.00 | 8.38 | 19.29 |
| 2025-11-26 | SANA | 0.00 | 8.38 | 19.96 |
| 2025-12-01 | SANA | 0.00 | 8.40 | 19.96 |
| 2025-12-02 | SANA | 0.00 | 8.40 | 19.96 |
| 2025-12-03 | SANA | 0.00 | 8.40 | 19.96 |
| 2025-12-04 | SANA | 0.00 | 8.40 | 19.96 |
| 2025-12-05 | SANA | 0.00 | 8.40 | 19.96 |
| 2025-12-08 | SANA | 0.00 | 8.41 | 19.96 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=SANA
589 360 ]
Last Quarter Act. EPS
-0.15
Avg. EPS Est. Current Quarter
-0.13
Avg. EPS Est. Next Quarter
-0.1
Insider Transactions
Institutional Transactions
8.41
Beta
1.95
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
3
Growth Score
19
Sentiment Score
70
Actual DrawDown %
89.6
Max Drawdown 5-Year %
Target Price
8
P/E
Forward P/E
PEG
P/S
P/B
6.22
P/Free Cash Flow
EPS
-0.97
Average EPS Est. Cur. Y
-0.75
EPS Next Y. (Est.)
-0.57
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1
Return on Equity vs Sector %
-146.9
Return on Equity vs Industry %
-132
EPS 1 7Days Diff
EPS 1 30Days Diff
0.04
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=SANA
589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=SANA
589 450 ]
Sana Biotechnology, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 194
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
stock quote shares SANA -Sana Biotechnology, Inc. Stock Price stock today
news today SANA -Sana Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SANA -Sana Biotechnology, Inc. yahoo finance google finance
stock history SANA -Sana Biotechnology, Inc. invest stock market
stock prices SANA
premarket after hours
ticker SANA
fair value insiders trading